SCHEMBL15049049

SCHEMBL15049049

O=C(O)c1sc(-c2cccc(Cl)c2)nc1OCc1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.47
NR4A2 P43354 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PTGER1 P34995 2/20 0.43
FABP4 P15090 1/20 0.42
FABP5 Q01469 1/20 0.42
FFAR1 O14842 1/20 0.41
SLC16A3 O15427 1/20 0.41
SLC16A1 P53985 1/20 0.41
MCTS1 Q9ULC4 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
RORB Q92753 2/20 0.40
TLR7 Q9NYK1 1/20 0.40
MCL1 Q07820 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
HRH3 Q9Y5N1 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15049251 0.91 NR4A2 (0.48) TRPM8NR4A2NPC1RAB9AFABP4
SCHEMBL15049031 0.89 TRPM8 (0.48) KMT2ATRPM8NR4A2NPC1RAB9A
SCHEMBL15049210 0.88 RAB9A (0.51) KMT2ATRPM8NR4A2NPC1RAB9A
SCHEMBL15049314 0.87 TRPM8 (0.64) KMT2ATRPM8
SCHEMBL15049261 0.84 KMT2A (0.52) KMT2ATRPM8NR4A2NPC1RAB9A
SCHEMBL15049220 0.83 NR4A2 (0.43) KMT2ATRPM8NR4A2NPC1RAB9A
SCHEMBL15049030 0.83 RAB9A (0.51) KMT2ATRPM8NR4A2NPC1RAB9A
SCHEMBL15049238 0.79 TRPM8 (0.47) TRPM8PTGER1FABP4FABP5FFAR1
SCHEMBL15049233 0.79 TRPM8 (0.48) KMT2ATRPM8NR4A2FFAR1SMN1; SMN2
SCHEMBL15048979 0.78 CDC7 (0.59) TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 EP claimed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 US claimed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 US claimed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 US claimed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 US claimed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 EP claimed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 WO claimed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 EP claimed
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 EP disclosed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 US disclosed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 US disclosed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 US disclosed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 US disclosed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 EP disclosed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 WO disclosed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129881-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 KMT2A 1792/4885TRPM8 1/4885NR4A2 873/4885
US-20140371276-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPV1 KMT2A 2307/4885TRPM8 1/4885NR4A2 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.